Herceptin plus tykerb makes breast cancer tumours 'disappear'
Results of a clinical trial of patients with HER2-positive breast cancer were presented at the European Breast Cancer Conference in Amsterdam. Patients treated with a combination of herceptin plus lapatinib showed significantly decreased tumour mass.
The Independent
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Conferences | Endocrinology | HER2 | Herceptin